JP2023522417A5 - - Google Patents

Info

Publication number
JP2023522417A5
JP2023522417A5 JP2022564304A JP2022564304A JP2023522417A5 JP 2023522417 A5 JP2023522417 A5 JP 2023522417A5 JP 2022564304 A JP2022564304 A JP 2022564304A JP 2022564304 A JP2022564304 A JP 2022564304A JP 2023522417 A5 JP2023522417 A5 JP 2023522417A5
Authority
JP
Japan
Prior art keywords
seq
cdr
amino acid
acid sequence
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022564304A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522417A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/060637 external-priority patent/WO2021214277A1/en
Publication of JP2023522417A publication Critical patent/JP2023522417A/ja
Publication of JP2023522417A5 publication Critical patent/JP2023522417A5/ja
Priority to JP2025017484A priority Critical patent/JP2025072512A/ja
Priority to JP2025119872A priority patent/JP2025157400A/ja
Pending legal-status Critical Current

Links

JP2022564304A 2020-04-24 2021-04-23 スルフヒドリル化合物およびその誘導体を用いた酵素および経路調節 Pending JP2023522417A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2025017484A JP2025072512A (ja) 2020-04-24 2025-02-05 スルフヒドリル化合物およびその誘導体を用いた酵素および経路調節
JP2025119872A JP2025157400A (ja) 2020-04-24 2025-07-16 スルフヒドリル化合物およびその誘導体を用いた酵素および経路調節

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20171356 2020-04-24
EP20171356.7 2020-04-24
PCT/EP2021/060637 WO2021214277A1 (en) 2020-04-24 2021-04-23 Enzyme and pathway modulation with sulfhydryl compounds and their derivatives

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2025017484A Division JP2025072512A (ja) 2020-04-24 2025-02-05 スルフヒドリル化合物およびその誘導体を用いた酵素および経路調節
JP2025119872A Division JP2025157400A (ja) 2020-04-24 2025-07-16 スルフヒドリル化合物およびその誘導体を用いた酵素および経路調節

Publications (2)

Publication Number Publication Date
JP2023522417A JP2023522417A (ja) 2023-05-30
JP2023522417A5 true JP2023522417A5 (https=) 2023-12-07

Family

ID=70464886

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022564304A Pending JP2023522417A (ja) 2020-04-24 2021-04-23 スルフヒドリル化合物およびその誘導体を用いた酵素および経路調節
JP2025017484A Pending JP2025072512A (ja) 2020-04-24 2025-02-05 スルフヒドリル化合物およびその誘導体を用いた酵素および経路調節
JP2025119872A Pending JP2025157400A (ja) 2020-04-24 2025-07-16 スルフヒドリル化合物およびその誘導体を用いた酵素および経路調節

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2025017484A Pending JP2025072512A (ja) 2020-04-24 2025-02-05 スルフヒドリル化合物およびその誘導体を用いた酵素および経路調節
JP2025119872A Pending JP2025157400A (ja) 2020-04-24 2025-07-16 スルフヒドリル化合物およびその誘導体を用いた酵素および経路調節

Country Status (18)

Country Link
US (2) US20230265204A1 (https=)
EP (2) EP4400515A3 (https=)
JP (3) JP2023522417A (https=)
KR (1) KR20230005172A (https=)
CN (1) CN115427443A (https=)
AR (1) AR121918A1 (https=)
AU (1) AU2021258475A1 (https=)
BR (1) BR112022021203A2 (https=)
CA (1) CA3178472A1 (https=)
CL (2) CL2022002885A1 (https=)
CR (2) CR20250142A (https=)
IL (1) IL296664A (https=)
MX (1) MX2022013173A (https=)
PE (1) PE20230078A1 (https=)
SA (1) SA522441031B1 (https=)
TW (2) TW202547878A (https=)
WO (1) WO2021214277A1 (https=)
ZA (1) ZA202210643B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3334167A1 (de) 1983-09-21 1985-04-04 Siemens AG, 1000 Berlin und 8000 München Halbleiterdiode
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
EP0700521B1 (en) 1993-05-28 2003-06-04 Baylor College Of Medicine Method and mass spectrometer for desorption and ionization of analytes
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
GB9717926D0 (en) 1997-08-22 1997-10-29 Micromass Ltd Methods and apparatus for tandem mass spectrometry
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
JP2002502086A (ja) 1998-01-23 2002-01-22 アナリティカ オブ ブランフォード インコーポレーテッド 表面からの質量分光測定
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
CA2471551C (en) * 2001-12-27 2014-09-30 Glycofi, Inc. Methods to engineer mammalian-type carbohydrate structures
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US8697082B2 (en) 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
JP2008501621A (ja) 2003-05-31 2008-01-24 マイクロメット アクツィエン ゲゼルシャフト B細胞関連疾患を処置するための二重特異性抗cd3、抗cd19抗体構築物を含む薬学的組成物
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
PL2583978T3 (pl) 2007-02-23 2016-07-29 Prothena Biosciences Ltd Co Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
PT2592148T (pt) 2007-10-12 2018-11-12 Hoffmann La Roche Expressão proteica de múltiplos ácidos nucleicos
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
CN102317316B (zh) 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
KR20110013687A (ko) 2009-08-03 2011-02-10 삼성모바일디스플레이주식회사 유기전계발광표시장치 및 그의 구동방법
EP2478013B1 (en) 2009-09-16 2018-10-24 F.Hoffmann-La Roche Ag Coiled coil and/or tether containing protein complexes and uses thereof
SI2723379T1 (sl) 2011-06-23 2019-03-29 Biogen International Neuroscience Gmbh Molekule, ki se vežejo ma anti alfa-sinuklein
WO2013026839A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
NO2748201T3 (https=) 2011-08-23 2018-05-12
RS63930B1 (sr) 2011-10-28 2023-02-28 Prothena Biosciences Ltd Humanizovana antitela koja prepoznaju alfa-sinuklein
DK2807188T3 (da) 2012-01-27 2019-10-07 Prothena Biosciences Ltd Humaniserede antistoffer, der genkender alpha-synuclein
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
JP2017501848A (ja) * 2013-11-19 2017-01-19 プロセナ バイオサイエンシーズ リミテッド 便秘症状からのレビー小体病の免疫療法のモニター
LT3071597T (lt) 2013-11-21 2020-10-12 F. Hoffmann-La Roche Ag Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai
BR112016017660B1 (pt) * 2014-02-27 2022-04-19 F. Hoffmann-La Roche Ag Método para a produção de uma glicoproteína recombinante
EP3177643B1 (en) 2014-08-04 2019-05-08 F.Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
EP3252078A1 (en) * 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
WO2018220099A1 (en) * 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
CA3051839A1 (en) * 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
JP2020528061A (ja) * 2017-07-26 2020-09-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト BET阻害剤、Bcl−2阻害剤及び抗CD20抗体を用いた併用療法
CA3108986A1 (en) * 2018-08-09 2020-02-13 Ventana Medical Systems, Inc. Determination of parkinson's disease

Similar Documents

Publication Publication Date Title
JP2023526774A5 (https=)
JP2021527431A5 (https=)
JP2023522417A5 (https=)
IL266756A (en) Human monoclonal antibodies that bind to MASP 2 and suppress MASP-dependent complement activation, methods for their production and uses
JP2021516976A5 (https=)
RU2451689C2 (ru) Новые антипролиферативные антитела
CN101978054B (zh) 能够与肝素结合性表皮生长因子样生长因子结合的单克隆抗体
JP2019535254A5 (ja) 抗pd−l1抗体および変異型
JP2018519263A5 (https=)
RU2010150348A (ru) Антитела к рецептору конечных продуктов глубокого гликирования (rage) и их применение
RU2008149918A (ru) Антитела к nkg2a и их применения
RU2009120052A (ru) Композиции и способы связывания сфингозин-1-фосфата
IL295381A (en) bcma-directed chimeric t-cell antigen receptor compounds and methods and uses thereof
JP2010509931A5 (https=)
RU2015118180A (ru) Антитела к бета-амилоиду
CN101511870A (zh) 能够与肝素结合性表皮生长因子样生长因子结合的单克隆抗体
JP2024086870A5 (https=)
JP2022528721A5 (https=)
JP2023549851A5 (https=)
JP2023549555A5 (https=)
JP2024509701A5 (https=)
AR121918A1 (es) Modulación de enzimas y vías con compuestos de sulfhidrilo y sus derivados
JP2020521490A5 (https=)
JP2021521201A5 (https=)
WO2024109877A1 (en) Antibody specifically binding to gcc